An in silico insight on the mechanistic aspects of gelsenicine toxicity: A reverse screening study pointing to the possible involvement of acetylcholine binding receptor

Gelsedine-type alkaloids are highly toxic plant secondary metabolites produced by shrubs belonging to the Gelsemium genus. Gelsenicine is one of the most concerning gelsedine-type alkaloids with a lethal dose lower than 1 mg/Kg in mice. Several reported episodes of poisoning in livestock and fatalit...

Full description

Saved in:
Bibliographic Details
Published inToxicology letters Vol. 386; pp. 1 - 8
Main Authors Pedroni, Lorenzo, Dorne, Jean Lou C.M., Dall’Asta, Chiara, Dellafiora, Luca
Format Journal Article
LanguageEnglish
Published Elsevier B.V 01.09.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Gelsedine-type alkaloids are highly toxic plant secondary metabolites produced by shrubs belonging to the Gelsemium genus. Gelsenicine is one of the most concerning gelsedine-type alkaloids with a lethal dose lower than 1 mg/Kg in mice. Several reported episodes of poisoning in livestock and fatality cases in humans due to the usage of Gelsemium plants extracts were reported. Also, gelsedine-type alkaloids were found in honey constituting a potential food safety issue. However, their toxicological understanding is scarce and the molecular mechanism underpinning their toxicity needs further investigations. In this context, an in silico approach based on reverse screening, docking and molecular dynamics successfully identified a possible gelsenicine biological target shedding light on its toxicodynamics. In line with the available crystallographic data, it emerged gelsenicine could target the acetylcholine binding protein possibly acting as a partial agonist against α7 nicotinic acetylcholine receptor (AChR). Overall, these results agreed with evidence previously reported and prioritized AChR for further dedicated analysis. [Display omitted] ●An in silico analysis based on a reverse screening has been applied.●A novel biological target of gelsenicine was identified.●A partial agonist activity against nicotinic acetylcholine receptor was described.●The activity reported here agreed and integrated that on NMDA-R already described.●The results obtained agreed with the gelsenicine’s TD data available so far.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0378-4274
1879-3169
DOI:10.1016/j.toxlet.2023.09.003